Articles tagged with: Milatuzumab-Doxorubicin
NewsFlash »
Revlimid Granted Approval For Multiple Myeloma In Japan – Celgene announced last week that Revlimid (lenalidomide) has been approved for the treatment of relapsed and refractory multiple myeloma in combination with dexamethasone (Decadron) in Japan. Revlimid will be available through Revmate, a proprietary distribution program. For more information, please read the Celgene press release.
Immunomedics Doses First Multiple Myeloma Patient With Milatuzumab-Doxorubicin Combination – Immunomedics has dosed the first patient in a Phase 1/2 study of its milatuzumab-based treatment for multiple myeloma. This treatment has doxorubicin (Adriamycin), a chemotherapy drug, bound to milatuzumab, an antibody. It will be evaluated for its efficacy as a treatment for relapsed and refractory multiple myeloma patients. For more information, please see the Immunomedics press release and the clinical trial description.
ImmunoGen And Sanofi-Aventis Announce Beginning Of Phase 1 Trial Of Potential New Myeloma Treatment – ImmunoGen Inc. and Sanofi-Aventis announced the initiation of a Phase 1 clinical trial of SAR650984, an antibody that targets cancer cells. In preclinical testing, SAR650984 was found to have anti-cancer effects, and is now being investigated as a treatment for relapsed and refractory multiple myeloma as well as other blood cancers. For more information, please refer to the ImmunoGen press release.
NewsFlash »
FDA Approves Clinical Trials For Milatuzumab-Doxorubicin Combination – The U.S. Food and Drug Administration (FDA) has approved Immunomedics Inc.'s investigational new drug application for its milatuzumab-based treatment for multiple myeloma. This drug has doxorubicin (Adriamycin), a chemotherapy drug, bound to milatuzumab, an antibody. It will be studied in Phase 1/2 clinical trials to evaluate safety and tolerability of the drug in patients with persistent or recurring myeloma. This drug is also undergoing preclinical studies for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. For more information, please see the Immunomedics press release.
IMF Patient And Family Seminar – On August 28-29 the International Myeloma Foundation (IMF) is holding its patient and family seminar in Edina, MN. The seminar includes many presentations by specialists, which focus on managing side effects, standard frontline therapy, and approaches to relapse treatment. For more information, please visit the IMF Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.